Loading company…
Amsterdam-based biotech developing modifier therapies for genetic disorders using its proprietary Cell-Seq platform.
Scenic Biotech B.V. develops modifier therapies for genetic disorders, using its proprietary Cell-Seq platform to identify modifier genes that can offset disease-causing mutations. Founded in 2017 in Amsterdam, Netherlands, and co-founded by Sebastian Nijman and Thijn Brummelkamp, the company is at the Series A stage and led by CEO Oscar Izeboud. Its March 10, 2022 Series A raised EUR 28.000 mn from investors including BioGeneration Ventures, BioMed Partners and Inkef Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in